Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA

What Was Tested

This registered phase 4 trial tested Romiplostim for anemia.

Treatment options for patients with aplastic anemia are very limited.

It had two arms (groups): Romiplostim+CsA (experimental) and CsA (experimental).

The registry classes the interventions as drug.

More on the Plan

At present, TPO-RAs including eltrombopag, lusutrombopag, romiplostim, and avatrombopag have been approved by FDA.

Who Took Part

Enrollment: 44 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥18 years old. Clearly diagnosed as untreated NSAA. Baseline liver and kidney function (ALT, AST, Cr) was less than 2 times the normal value. No active infection; Not pregnant or breastfeeding. Agree to sign the consent form.

The full record lists 7 inclusion and 12 exclusion criteria; among the exclusions: pancytopenia caused by other causes, such as myelodysplastic syndrome (mds); there is cytogenetic evidence of clonal hematologic bone marrow diseases (mds, aml); had received hematopoietic stem cell transplantation (hsct) before enrollment.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Romiplostim and who got the comparison, which limits bias.

Groups ran in parallel: each of the anemia participants stayed in one arm throughout.

Nothing was hidden in this open-label Romiplostim study: the anemia participants and staff both knew the treatment.

It started in 2023-08 with completion listed for 2024-12.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): overall response rate (ORR) (time frame: 3, 6 months). complete response rate (CRR) (time frame: 3, 6 months).

It also tracked 1 secondary outcome, for example adverse event rate.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Romiplostim in 44 people with anemia.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Romiplostim compound page, Anemia research.